1
Stéphane De Lombaert
Bakthavatchalam Rajagopal, Blum Charles A, Brielmann Harry, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, Hutchison Alan, Yoon Taeyoung, Zheng Xiaozhang: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Bakthavatchalam Rajagopal, Blum Charles A, Brielmann Harry, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, Hutchison Alan, Yoon Taeyoung, Zheng Xiaozhang, ALEXANDER John B, January 27, 2005: WO/2005/007648 (17 worldwide citation)

Biaryl piperazinyl -pyri dine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with path ...


2
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Stéphane De Lombaert, Taeyoung Yoon, Xiaozhang Zheng: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, July 28, 2009: US07566712 (6 worldwide citation)

Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathologic ...


3
Yves Ducharme, Jacques Y Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien: Phenyl heterocycles as cox-2 inhibitors. Merck Frosst Canada, Curtis C Panzer, David L Rose, December 12, 1995: US05474995 (196 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases, ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.


4
Chakravarty Prasun K, Greenlee William J, Mantlo Nathan B, Patchett Arthur A, Walsh Thomas F: Substituted imidazo-fused 6-membered heterocycles as angiotensin ii antagonists.. Merck & Co, December 5, 1990: EP0400974-A2 (191 worldwide citation)

Substituted Imidazo-fused 6-membered heterocycles of structural formula: wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.


5
Belleau Bernard, Belleau Pierette, Nguyen Ba Nghe: Substituted -1,3-oxathiolanes with antiviral properties.. Iaf Biochem Int, August 16, 1990: EP0382526-A2 (123 worldwide citation)

Disclosed are compounds of the formula wherein R1 is hydrogen; R2 is a purine or pyrimidine base or an analogue or derivative thereof; Z is S, S=O or SO2; and pharmaceutically acceptable derivatives thereof. Also described are use of the compounds as antiviral agents, pharmaceutical formulations, an ...


6
Coates William John, Flynn Seyn Thomas, Rawlings Derek Anthony: Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them.. Smith Kline French Lab, December 20, 1989: EP0347146-A2 (101 worldwide citation)

Compounds of the formula (1) : or pharmaceutically acceptable salts thereof as described, wherein is a pyridine, pyrazine or triazine ring; R is C1-6alkyl, C2-6alkenyl, C3-5cycloalkylC1-6alkyl, or C1-6alkyl substituted by 1 to 6 fluoro groups; R is C1-6alkylthio, C1-6alkylsulphonyl, C1-6alkoxy, hydr ...


7

8
Bertin John, Grant Ethan P: Method for treating cancer. Synta Pharmaceuticals, Bertin John, Grant Ethan P, HSI Jeffrey D, November 30, 2006: WO/2006/128129 (89 worldwide citation)

The invention relates to a method for treating cancers using compounds that modulate the activity of c-Rel.


9

10
Belleau Bernard, Nguyen Ba Nghe: 1,3-oxathiolanes useful in the treatment of hepatitis.. Iaf Biochem Int, November 25, 1992: EP0515144-A1 (67 worldwide citation)

The present invention relates to the use of nucleoside analogues in the treatment of viral infections. More specifically it is concerned with the use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis, in particular hepatitis B.